<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073409</url>
  </required_header>
  <id_info>
    <org_study_id>NTM-OB-17 (PREDICT PART A)</org_study_id>
    <nct_id>NCT02073409</nct_id>
  </id_info>
  <brief_title>PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an
      increasingly common finding, and the lack of an evidenced-based approach to the diagnosis of
      NTM disease has been identified as one of the greatest unmet needs within the CF community.
      Current evidence predicts that the prevalence of NTM will remain relatively high in the CF
      population. Approaches to NTM disease diagnosis differ widely between centers. This study is
      observational and follows current best practices. The study will help standardize the
      diagnosis and collect relevant data associated with the diagnosis of NTM disease to build a
      framework for future therapeutic trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion meeting the diagnosis of NTM disease</measure>
    <time_frame>12 months intervals following study enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to PREDICT protocol: number of respiratory cultures obtained per participant per year, withdrawals and major deviations from protocol</measure>
    <time_frame>12 months intervals following study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and prevalence of NTM species/subspecies by geographical region</measure>
    <time_frame>12 months intervals following study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eligible NTM positive individuals with CF enrolling in PREDICT by site</measure>
    <time_frame>12 months intervals following study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of PREDICT participants with NTM disease diagnosis who enroll in Part B PATIENCE</measure>
    <time_frame>12 months intervals following study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters and outcomes (FEV1, growth parameters, CFQ-R)</measure>
    <time_frame>12 months intervals following study enrollment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients</arm_group_label>
    <description>Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples collected may include serum, sputum, whole blood, breath, urine, and NTM isolates.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female subjects with CF age 6 years and older who have a positive sputum culture
        for NTM.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent (and assent when applicable) obtained from participant or
             participant's legal representative

          2. Enrolled in the CFF Patient Registry (CFF PR)

          3. Be willing and able to adhere to study procedures in the context of clinical care, and
             other protocol requirements

          4. Male or female participant â‰¥ 6 years of age at enrollment who are able to reliably
             expectorate sputum and/or willing to undergo sputum induction (if necessary)

          5. Diagnosis of CF consistent with the 2017 CFF Guidelines

          6. NTM positive for a species or sub-species in the 2 years prior to enrollment that has
             never been treated.

          7. Willing to discontinue chronic azithromycin use for the duration of the study

        Exclusion Criteria:

          1. Prior or ongoing antibiotic treatment of the same NTM species or sub-species for which
             the patient is being considered for this study

          2. History of solid organ or hematological transplantation

          3. Has any other condition that, in the opinion of the Site Investigator/designee, would
             preclude informed consent or assent, make study participation unsafe, complicate
             interpretation of study outcome data, or otherwise interfere with achieving the study
             objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry A Nick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey Martiniano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Jones, RN</last_name>
    <phone>(303) 398-1265</phone>
    <email>jonesm@njhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meg Anthony, MSW</last_name>
    <phone>(720) 777-2945</phone>
    <email>Meg.Anthony@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CFF Pediatric Program, University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katie Brand</last_name>
      <phone>205-638-9410</phone>
      <email>kbrand@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>George M Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Anthony, MSW</last_name>
      <phone>720-777-2945</phone>
      <email>Meg.Anthony@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Stacey Martiniano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ellington, RN</last_name>
      <phone>303-270-2333</phone>
      <email>ellingtons@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jerry A Nick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Rykiel</last_name>
      <phone>410-614-1409</phone>
      <email>mrykiel1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Keira Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Pediatric Program University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Kruse</last_name>
      <phone>734-615-3266</phone>
      <email>dmkruse@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Lindsay Caverly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Pediatric Program, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Kramer</last_name>
      <phone>215-305-4675</phone>
      <email>ARK2187@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Emily DiMango, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelsey Haywood</last_name>
      <phone>919-445-2855</phone>
      <email>kelsey_haywood@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Goralski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, The University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Keller</last_name>
      <phone>214-648-2817</phone>
      <email>Ashley.Keller@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Raksha Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Pediatric Program Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon McNamara</last_name>
      <phone>206-987-3921</phone>
      <email>sharon.mcnamara@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Gambol</last_name>
      <phone>206-543-7382</phone>
      <email>TGambol@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Moira Aitken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jerry A. Nick, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Nontuberculous Mycobacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

